At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 28 enrolled
Drug / intervention
ABBV-399drug
Likely dose
ABBV-399 2.7 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of ABBV-399 in Patients With C-Met Positive Stage IV or Recurrent Squamous Cell Lung Cancer (LUNG-MAP SUB-STUDY)
In Brief
A Phase 2 clinical trial evaluating ABBV-399 for Recurrent Squamous Cell Lung Carcinoma and Stage IV Squamous Cell Lung Carcinoma AJCC V7. Completed, enrolled 28 participants across 1 site.
Detailed Summary
S1400K of Lung-MAP seeks to evaluate the overall response rate with ABBV-399 (Process II) in patients with c-MET positive SCCA. S1400K is a biomarker-driven study for patients with Stage IV or recurrent squamous cell lung cancer, who have c-MET positive squamous cell tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
Enrollment StartMar 2018
First PostedJul 2018
Primary CompletionDec 2019
Study CompletionJul 2021
TodayJul 2026
First PostedJul 2, 2018
Enrollment StartMar 16, 2018
Primary CompletionDec 21, 2019
Study CompletionJul 30, 2021
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 8 years ago
Interventions
ABBV-399drug
ABBV-399 (Process II), 2.7 mg/kg IV over 30 ± 10 minutes, Day 1, Every 21 days